kinder and gentler next-generation ADCs
About Kivu Bioscience
As a company focused on rapidly advancing next generation transformative assets, we leverage our expertise to efficiently progress programs to clinical proof of concept.
Guided by rigorous science and a commitment to addressing unmet medical needs, our experienced team collaborates with global partners and key opinion leaders to accelerate the delivery of life changing antibody-drug conjugates (ADCs) that aim to conquer cancer.
Mission
We are inspired by patients and fueled by data to accelerate the development of novel cancer medicines.
Vision
To conquer cancer and deliver transformative ADCs that allow our patients to live longer and thrive.
Science
At Kivu Bioscience, we leverage advanced, next-generation proprietary ADC technologies to deliver more precise and effective cancer treatments. Utilizing Synaffix‘s site-specific conjugation platform, including the cutting-edge GlycoConnect™ technology, Kivu’s proprietary approach creates highly stable ADCs with optimized linker and payload combinations, designed to maximize therapeutic efficacy while minimizing off-tumor toxicity. By targeting aspargine-297, GlycoConnect™ produces a clean, highly homogenous product, offering a clear manufacturing advantage over other conjugation technologies. With state-of-the-art innovations in conjugation and payload delivery, we are shaping the future of targeted oncology therapies with a commitment to improving patient outcomes and treatment tolerability.
Kivu programs employ three technology pillars to deliver best-in-class ADCs by enhancing homogeneity, stability and potency.
Technology Pillars
Homogeneity
Stability
A hydrophilic linker increases polarity which reduces payload hydrophobicity and aggregation, resulting in improved payload retention. This enhancement positively impacts both manufacturability and efficacy by increasing ADC stability. Enhanced plasma stability further reduces off-target side effects, improving the safety profile for patients.
Potency
We utilize proprietary, clinically validated payloads with higher potency compared to previous payloads in the same class. These payloads demonstrate high permeability, bystander killing capability, and resistance to drug efflux transporters, maximizing therapeutic impact within tumor cells.
Pipeline
Indication
Development Candidate
IND-Enabling
Phase 1
KIVU-107
Indication:
Candidate
IND-Enabling
Phase 1
KIVU-305
Indication:
Candidate
IND-Enabling
Phase 1
KIVU-202
Indication:
Candidate
IND-Enabling
Phase 1
Who we are
Our team is driven by a passion for innovation and collaboration, working together to bring life-changing cancer treatments to the world.
Team
Board of Directors
Careers
A Culture of Belonging
Kivu Bioscience: A Culture of Diversity, Equity, Inclusion, and Belonging. At Kivu Bioscience, we are driven by our mission to develop groundbreaking therapies that advance oncology treatment and improve patients’ lives. Our success stems from the strength and diversity of our team, and we are deeply committed to creating an environment where every individual can thrive.
We foster a collaborative, inclusive culture built on intellectual curiosity, innovation, and a shared passion for making a difference. Our fast-paced environment encourages continuous learning, and we are fully invested in the recruitment, training, and professional growth of each team member.
Join Us
Kivu Bioscience is seeking motivated, dynamic individuals who are inspired to join our mission of advancing next-generation ADCs for oncology. If you are passionate about transforming cancer treatment and making a meaningful impact, we’d love to connect with you.
To be considered for a position at Kivu Bioscience, please send us a message using the button below.
Shaping the future of targeted oncology ADCs
We are commited to improving patient outcomes and treatment tolerability